undamentalytics Newsletter

Volitionrx LTD insider trading

Every open-market purchase and sale by Volitionrx LTD's officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

Insider purchase Insider sale Marker size reflects trade value. Weekly closes adjusted for splits; may be delayed.
Volitionrx LTD insider open-market trades
DateInsiderTrade SharesPriceValue 1M after 3M after 6M after

From insiders' Form 4 filings with the SEC: open-market purchases and sales only (awards, option exercises and shares withheld for tax are excluded), combined to one line per insider per day. "Plan" marks trades the filing says were made under a pre-set Rule 10b5-1 trading plan, which are scheduled in advance. Price changes run from the close on the trade date; hover a figure for the change relative to the S&P 500. Past moves don't predict future ones.

Does following Volitionrx LTD’s insiders pay?

From November 18, 2013 to October 15, 2025, 14 insiders reported 51 open-market purchases and 13 sales not made under a pre-set plan in Volitionrx LTD. Twelve months after each purchase was reported, the shares were −62.2% against the S&P 500 on average (median −62.2%), over 1 purchase with a full year of prices; 0% beat the index. After sales, the shares moved −65.2% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on October 21, 2019 into $6,503 by November 2, 2026, −6.0% a year. It held shares 14% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $14,215 (+5.1% a year), and held throughout $27,870 (+15.7%).

$0$10.0k$20.0k$30.0k 20192020202120222023202420252026 $27.9k$14.2k$6.5k
Copying Volitionrx LTD's insidersS&P 500, same days investedS&P 500, held throughout $10,000 copying every open-market purchase by Volitionrx LTD's insiders from October 21, 2019, before costs and taxes, marked weekly. Uninvested money earns the Treasury bill rate; the portfolio held shares 14% of the time.
Volitionrx LTD: each insider's record
InsiderRolePurchases12 months after their purchasesBeat the S&P 500Sales12 months after their salesLatest report
Innes Guy Archibald Director 18 — — 0 — October 15, 2025
Reynolds Cameron John President and CEO 8 — — 1 — October 15, 2025
Faulkes Martin Charles Director 7 — — 1 — September 1, 2023
Micallef Jacob Vincent Chief Scientific Officer 7 — — 0 — May 19, 2025
Terrell Jason Bradley Md Chief Medical Officer 0 — — 7 −72.0% (1) June 7, 2022
Butera Salvatore Thomas CEO - Volition Veterinary 5 — — 0 — June 6, 2023
Eight Corp Ltd 10% owner 0 — — 2 −58.5% (1) January 3, 2024
Still Timothy I Director 2 — — 0 — October 15, 2025
Colman Alan Director 1 — — 0 — September 29, 2014
Concord International Inc. Secretary 0 — — 1 — September 3, 2014
Cotterford Co Ltd 10% owner 1 −62.2% (1) 0% 0 — October 18, 2019
Hever Investments Ltd 10% owner 0 — — 1 — December 20, 2023
Kratochvil David Matthew Chief Financial Officer 1 — — 0 — October 6, 2016
Rootsaert Rodney Gerard Secretary 1 — — 0 — August 17, 2017

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

When several insiders traded Volitionrx LTD

Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Volitionrx LTD in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 1 buying crowd with six months of prices, it averaged −20.7% against the index. One company's history is too short to judge by; the test across every company is the better guide.

MonthCrowd3 months on, vs S&P 5006 months12 months
October 31, 20192 buying−23.1%−20.7%−56.5%

Colours show whether the crowd was right: green when buyers were followed by a rise above the index, or sellers by a fall below it. Total returns from the month end; past patterns are not a forecast.

← Back to Volitionrx LTD · Funds · Politicians